- Response to Letter Regarding Article, “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis”
-
Park KW
- KMID: 2525233
- J Lipid Atheroscler.
- 2022 Jan;11(1):87-88.
- doi: 10.12997/jla.2022.11.1.87
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter by Awadhesh Kumar Singh Regarding Article, “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis”
-
Singh AK, Singh R
- KMID: 2525234
- J Lipid Atheroscler.
- 2022 Jan;11(1):84-86.
- doi: 10.12997/jla.2022.11.1.84
-
- CITED
-
- Close
- SHARE
-
- Close
- Individualized Treatment for Patients With Familial Hypercholesterolemia
-
Tada H, Takamura M, Kawashiri Ma
- KMID: 2525236
- J Lipid Atheroscler.
- 2022 Jan;11(1):39-54.
- doi: 10.12997/jla.2022.11.1.39
Familial hypercholesterolemia (FH) is one of the most common and, therefore, important inherited disorders in preventive cardiology. This disease is mainly caused by a single pathogenic mutation in the low-density... -
- CITED
-
- Close
- SHARE
-
- Close
- Metabolism and Health Impacts of Dietary Sugars
-
Alam YH, Kim R, Jang C
- KMID: 2525231
- J Lipid Atheroscler.
- 2022 Jan;11(1):20-38.
- doi: 10.12997/jla.2022.11.1.20
Consumption of excessive amounts of added sugars and their effects on human health has been a major concern in the last several decades. Epidemiological data suggest that the incidence of... -
- CITED
-
- Close
- SHARE
-
- Close
- SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
-
Saucedo-Orozco H, Voorrips SN, Yurista SR, de Boer RA, Westenbrink BD
- KMID: 2525232
- J Lipid Atheroscler.
- 2022 Jan;11(1):1-19.
- doi: 10.12997/jla.2022.11.1.1
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as powerful drugs that can be used to treat heart failure (HF) patients, both with preserved and reduced ejection fraction and in the presence... -
- CITED
-
- Close
- SHARE
-
- Close
- Assessing the Validity of the Criteria for the Extreme Risk Category of Atherosclerotic Cardiovascular Disease: A Nationwide Population-Based Study
-
Kim KS, Hong S, Han K, Park CY
- KMID: 2525235
- J Lipid Atheroscler.
- 2022 Jan;11(1):73-83.
- doi: 10.12997/jla.2022.11.1.73
Objective: To validate the criteria for the extreme risk category for atherosclerotic cardiovascular disease (ASCVD). Methods: An observational cohort study of 35,464 individuals with established ASCVD was performed using the National... -
- CITED
-
- Close
- SHARE
-
- Close
- Correction to: “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis”
-
Jeon WK, Kang J, Kim HS, Park KW
- KMID: 2525229
- J Lipid Atheroscler.
- 2022 Jan;11(1):89-101.
- doi: 10.12997/jla.2022.11.1.89
Objective: Recent studies have raised concerns about the cardiovascular safety of dipeptidyl peptidase-4 (DPP4) inhibitors. We performed a systematic review and meta-analysis to compare the cardiovascular outcomes of sulfonylureas (SUs)... -
- CITED
-
- Close
- SHARE
-
- Close
- Profiling of RNA-binding Proteins Interacting With Glucagon and Adipokinetic Hormone mRNAs
-
Ko S, Yeom E, Chun YL, Mun H, Howard-McGuire M, Millison NT, Jung J, Lee KP, Lee C, Lee KS, Delaney JR, Yoon JH
- KMID: 2525230
- J Lipid Atheroscler.
- 2022 Jan;11(1):55-72.
- doi: 10.12997/jla.2022.11.1.55
Objective: Glucagon in mammals and its homolog (adipokinetic hormone [AKH] in Drosophila melanogaster) are peptide hormones which regulate lipid metabolism by breaking down triglycerides. Although regulatory mechanisms of glucagon and... -
- CITED
-
- Close
- SHARE
-
- Close
